ArticleScientific reports2025
Increased serum uric acid to creatinine ratio is associated with metabolic dysfunction associated steatotic liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the correlation between the serum uric acid to creatinine ratio (SUA/SCr) and the severity of hepatic steatosis in individuals with MASLD. A total of 34,981 individuals were measured the controlled attenuated parameter (CAP) using transient elastography (TE), then we studied the association between SUA/SCr and the severity of hepatic steatosis defined with the value of CAP. A cohort of 2179 individuals without MASLD were followed up to investigate the relationship between SUA/SCr and the incidence of MASLD during the following 33 months. After adjusting for confounding factors, smooth fitting curve and threshold saturation analysis showed that SUA/SCr exhibited a significant positive correlation with CAP (P < 0.0001), with different inflection points in sex, BMI and age subgroups. Logistic regression analysis showed that SUA/SCr demonstrated a certain degree of predictive value for MASLD (P < 0.001). In followed-up population, individuals with higher SUA/SCr exhibited a significantly increased cumulative incidence of MASLD (P = 0.0008). Increased SUA/SCr levels are associated with the severity of hepatic steatosis in MASLD, is an independent risk factor for MASLD. Individuals with elevated levels of SUA/SCr are at a higher risk of developing MASLD. Maybe SUA/SCr could be considered as a useful biomarker for MASLD in clinical work, although the predictive value is limited, and further validation and combined usage with other markers are necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.